Receptors GLP-1 GLP-1 + GIP GLP-1 + GIP + Glucagon Class Single-agonist Dual-agonist Triple-agonist Generation First Second Third Brand Names Ozempic / Wegovy Mounjaro / Zepbound Not yet approved Phase 2 Weight Loss (peak) ~14.9% ~20.9% 24.2% Approval Status FDA approved FDA approved Phase 3 trials A common question: is the difference between 20.9% (tirzepatide) and 24.2% (retatrutide) really that significant
The clinician must review the specific medications, dosing, treatment response, side effects, and relevant health conditions
Hims & Hers' latest move caps off a rocky relationship with the drugmaker
Skin and cosmetic peptides GHK-Cu appears prominently in their catalog, marketed toward researchers studying copper peptide effects on skin biology
Trusted Source for Research Peptides We provide high-quality research peptides with a focus on purity, consistency, and transparency
It encourages consistency, personalization, and integration with lifestyle habits such as strength training, adequate protein intake, sleep, and stress management